Takeda Pharmaceutical TSE 4502 Valuation Check After Positive Zasocitinib Phase 3 Psoriasis Data

Takeda Pharmaceutical (TSE:4502) is back in focus after releasing new Phase 3 data for its investigational TYK2 inhibitor zasocitinib in moderate to severe plaque psoriasis, paired with plans for future regulatory filings.

See our latest analysis for Takeda Pharmaceutical.

The zasocitinib data appear to have arrived during a strong run for the shares, with a 90-day share price return of 19.92% and a 1-year total shareholder return of 33.75% suggesting momentum has been building over both shorter and longer periods.

If this kind of pipeline news has your attention, it can be useful to scan for other potential opportunities in healthcare using our dedicated screener, starting with 7 healthcare AI stocks.

With the shares up strongly over 1 year and trading slightly above the average analyst price target, the key question now is whether Takeda still trades at a meaningful discount to its intrinsic value or if the market already reflects expectations for future growth.

Most Popular Narrative: 2.5% Overvalued

With Takeda closing at ¥5,840 against a widely followed fair value estimate of about ¥5,697, the current price sits slightly above that narrative anchor, and the assumptions behind it focus heavily on the pipeline and earnings rebuild story.

The anticipated moderation and eventual stabilization of VYVANSE generic erosion after FY2025 will remove a major headwind for revenues, allowing Takeda’s core growth and launch products to drive top-line and earnings recovery going forward.

Read the complete narrative.

Want to see what revenue mix and margin profile would have to line up for that recovery arc to hold? The narrative leans on modest top line expansion, much faster earnings growth and a rich future earnings multiple that sits well above the wider pharmaceuticals group. Curious how those ingredients combine into that fair value path and what has to go right along the way?

Result: Fair Value of ¥5,696.87 (OVERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this hinges on generic and biosimilar pressure easing, as well as on key late stage assets avoiding delays, safety surprises or underwhelming commercial uptake.

Find out about the key risks to this Takeda Pharmaceutical narrative.

Another View: Cash Flows Tell a Different Story

While the consensus fair value of about ¥5,697 suggests Takeda is 2.5% overvalued on analyst targets, the SWS DCF model points in the opposite direction, with a future cash flow value of ¥14,743.23 per share. That implies the current ¥5,840 price sits at a steep discount. Which yardstick do you trust more for a long term thesis?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Takeda Pharmaceutical for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 19 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

Next Steps

With mixed signals on valuation and sentiment, now is a good time to look through the details yourself and decide what truly matters. To weigh both sides of the story in one place, start with these 2 key rewards and 4 important warning signs.

Looking for more investment ideas?

If you stop here, you only see one piece of the puzzle. Use the tools available and keep building a watchlist of ideas that genuinely fit your goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com